The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries

This is the authors' abstract. We don't add key points for this paper.

It is up to all stakeholders to capitalize on the opportunity that biosimilars provide, mostly by committing to transparent collaboration, to make biotherapeutics accessible to all, regardless of region or country of residence.